Form 4 for VKTX Viking Therapeutics, Inc.
Accepted 2025-01-06 00:00:00 ET · period of report 2025-01-03 · accession 0000950170-25-002486 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-01-06 | 2025-01-03 | VKTX | Mancini Marianna | COO | A - Grant | $0.00 | +66.2K | 406.7K | +19% | $0 |
| DM | 2025-01-06 | 2025-01-06 | VKTX | Mancini Marianna | COO | S - Sale | $42.75 | -54.2K | 374.1K | -13% | -$2.32M |
| D | 2025-01-06 | 2025-01-03 | VKTX | Mancini Marianna | COO | A - Grant | $0.00 | +37.2K | 37.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.00001 per share | 2025-01-03 | A | A | 21,667 | $0.00 | 428,349 | D | — | — | (F2) The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on January 3, 2025 upon the achievement of a non-financial performance goal. |
| 2 | Common | Common Stock, par value $0.00001 per share | 2025-01-06 | S | D | 49,115 | $42.69 | 379,234 | D | — | — | (F3) These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.20 to $43.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 3 | Common | Common Stock, par value $0.00001 per share | 2025-01-03 | A | A | 44,533 | $0.00 | 406,682 | D | — | — | (F1) Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. |
| 4 | Common | Common Stock, par value $0.00001 per share | 2025-01-06 | S | D | 5,100 | $43.32 | 374,134 | D | — | — | (F3) These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards. (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.20 to $43.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 5 | Derivative | Stock Option (Right to Buy) | 2025-01-03 | A | A | 37,200 | $0.00 | 37,200 | D | $42.89 · 2026-01-03 to 2035-01-03 | 37,200 Common Stock | (F6) 25% of the shares subject to the option will vest on each anniversary of the grant date. |